Cargando…

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

BACKGROUND: Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of ≥5 cells/7.5 ml are associated with poor CRPC outcome. OBJECTIVE: To determine the value of a ≥30% CTC decline as a treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorente, David, Olmos, David, Mateo, Joaquin, Bianchini, Diletta, Seed, George, Fleisher, Martin, Danila, Daniel C., Flohr, Penny, Crespo, Mateus, Figueiredo, Ines, Miranda, Susana, Baeten, Kurt, Molina, Arturo, Kheoh, Thian, McCormack, Robert, Terstappen, Leon W.M.M., Scher, Howard I., de Bono, Johann S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568108/ https://www.ncbi.nlm.nih.gov/pubmed/27289566 http://dx.doi.org/10.1016/j.eururo.2016.05.023

Ejemplares similares

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles
por: Nanou, Afroditi, et al.
Publicado: (2018)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients
por: Nanou, Afroditi, et al.
Publicado: (2018)

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
por: Crespo, M, et al.
Publicado: (2015)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
por: Lozano, Rebeca, et al.
Publicado: (2021)

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018)

Detection of cancer before distant metastasis
por: Coumans, Frank AW, et al.
Publicado: (2013)

Metastasis and Circulating Tumor Cells
por: van Dalum, Guus, et al.
Publicado: (2012)

Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis
por: Barradas, Ana M.C., et al.
Publicado: (2013)

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
por: Bianchini, D, et al.
Publicado: (2013)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Leukocyte-Derived Extracellular Vesicles in Blood with and without EpCAM Enrichment
por: Nanou, Afroditi, et al.
Publicado: (2019)

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)
por: Andree, Kiki C., et al.
Publicado: (2018)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS
por: Swennenhuis, Joost F, et al.
Publicado: (2013)

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
por: Goodman, O B, et al.
Publicado: (2014)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
por: Mateo, Joaquin, et al.
Publicado: (2020)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
por: Carreira, Suzanne, et al.
Publicado: (2021)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Pixel-Cluster Counting Luminosity Measurement in ATLAS
por: McCormack, William Patrick
Publicado: (2016)

Pixel-Cluster Counting Luminosity Measurement In ATLAS
por: McCormack, William Patrick
Publicado: (2016)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*
por: Wilbaux, M, et al.
Publicado: (2015)

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients
por: Mayado, Andrea, et al.
Publicado: (2020)

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
por: de Bono, Johann S., et al.
Publicado: (2016)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
por: Bianchini, Diletta, et al.
Publicado: (2017)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
por: Zeune, Leonie L., et al.
Publicado: (2018)

Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer
por: Franken, Bas, et al.
Publicado: (2012)

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
por: Ong, M, et al.
Publicado: (2014)

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer
por: Ligthart, Sjoerd T., et al.
Publicado: (2013)

Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features
por: Perez-Lopez, Raquel, et al.
Publicado: (2018)

Technical Basics and Clinical Benefits of Photon-Counting CT
por: Flohr, Thomas, et al.
Publicado: (2023)

Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival
por: Ligthart, Sjoerd T., et al.
Publicado: (2011)

Label-free identification and chemical characterisation of single extracellular vesicles and lipoproteins by synchronous Rayleigh and Raman scattering
por: Enciso-Martinez, Agustin, et al.
Publicado: (2020)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
por: Paschalis, Alec, et al.
Publicado: (2019)

The promise of circulating tumor cell analysis in cancer management
por: Mateo, Joaquin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i84l8f4ci6vjd7iobgp00gj4kq